144 related articles for article (PubMed ID: 15982356)
1. The measurement of urinary hydroxyurea in sickle cell anaemia.
Dalton RN; Turner C; Dick M; Height SE; Awogbade M; Inusa B; Okpala I; O'Driscoll S; Thein SL; Rees DC
Br J Haematol; 2005 Jul; 130(1):138-44. PubMed ID: 15982356
[TBL] [Abstract][Full Text] [Related]
2. Plasma and urine hydroxyurea levels might be useful in the management of adult sickle cell disease.
Bachir D; Hulin A; Huet E; Habibi A; Nzouakou R; El Mahrab M; Astier A; Galacteros F
Hemoglobin; 2007; 31(4):417-25. PubMed ID: 17994375
[TBL] [Abstract][Full Text] [Related]
3. Enalapril and hydroxyurea therapy for children with sickle nephropathy.
Fitzhugh CD; Wigfall DR; Ware RE
Pediatr Blood Cancer; 2005 Dec; 45(7):982-5. PubMed ID: 15704213
[TBL] [Abstract][Full Text] [Related]
4. Sickle cell patients find a brand New World.
Noonan SS
N J Med; 1999 Aug; 96(8):23-5. PubMed ID: 10457727
[TBL] [Abstract][Full Text] [Related]
5. Hydroxyurea therapy for sickle cell disease in community-based practices: a survey of Florida and North Carolina hematologists/oncologists.
Zumberg MS; Reddy S; Boyette RL; Schwartz RJ; Konrad TR; Lottenberg R
Am J Hematol; 2005 Jun; 79(2):107-13. PubMed ID: 15929107
[TBL] [Abstract][Full Text] [Related]
6. Hydroxyurea for children with sickle cell disease.
Heeney MM; Ware RE
Pediatr Clin North Am; 2008 Apr; 55(2):483-501, x. PubMed ID: 18381097
[TBL] [Abstract][Full Text] [Related]
7. Hydroxyurea in sickle cell disease patients from Eastern Saudi Arabia.
Al-Jam'a AH; Al-Dabbous IA
Saudi Med J; 2002 Mar; 23(3):277-81. PubMed ID: 11938415
[TBL] [Abstract][Full Text] [Related]
8. The association of oral hydroxyurea therapy with improved cognitive functioning in sickle cell disease.
Puffer E; Schatz J; Roberts CW
Child Neuropsychol; 2007 Mar; 13(2):142-54. PubMed ID: 17364571
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of clinical response by hydroxyurea in 132 patients with major sickle cell anemia].
Elira Dokekias A; Okandze Elenga JP; Ndinga J; Sanogo I; Sangare A
Tunis Med; 2005 Jan; 83(1):32-7. PubMed ID: 15881719
[TBL] [Abstract][Full Text] [Related]
10. Circulating endothelin-3 levels in patients with sickle cell disease during hydroxyurea treatment.
Makis AC; Hatzimichael EC; Kolios G; Bourantas KL
Haematologica; 2004 Mar; 89(3):360-1. PubMed ID: 15020278
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic and genotoxic monitoring of sickle cell anaemia patients treated with hydroxyurea.
Khayat AS; Antunes LM; Guimarães AC; Bahia MO; Lemos JA; Cabral IR; Lima PD; Amorim MI; Cardoso PC; Smith MA; Santos RA; Burbano RR
Clin Exp Med; 2006 Mar; 6(1):33-7. PubMed ID: 16550342
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary hypertension in children and young adults with sickle cell disease: evidence for familial clustering.
Dahoui HA; Hayek MN; Nietert PJ; Arabi MT; Muwakkit SA; Saab RH; Bissar AN; Jumaa NM; Farhat FS; Dabbous IA; Bitar FF; Abboud MR
Pediatr Blood Cancer; 2010 Mar; 54(3):398-402. PubMed ID: 19827138
[TBL] [Abstract][Full Text] [Related]
13. Hydroxyurea therapy: improving the lives of patients with sickle cell disease.
Anderson N
Pediatr Nurs; 2006; 32(6):541-3. PubMed ID: 17256291
[TBL] [Abstract][Full Text] [Related]
14. Hydroxyurea for sickle cell anemia.
Bachmeyer C; Aractingi S; Lionnet F
N Engl J Med; 2008 Jul; 359(1):98; author reply 98-9. PubMed ID: 18609755
[No Abstract] [Full Text] [Related]
15. Two assays to evaluate potential genotoxic effects of hydroxyurea in sickle cell disease patients.
Rodríguez A; Kouegnigan L; Ferster A; Cotton F; Duez P
Hemoglobin; 2012; 36(6):545-54. PubMed ID: 23094637
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of hydroxyurea for children and adolescents with sickle cell disease.
Wiczling P; Liem RI; Panepinto JA; Garg U; Abdel-Rahman SM; Kearns GL; Neville KA
J Clin Pharmacol; 2014 Sep; 54(9):1016-22. PubMed ID: 24729271
[TBL] [Abstract][Full Text] [Related]
17. Effects of hydroxyurea on the membrane of erythrocytes and platelets in sickle cell anemia.
Covas DT; de Lucena Angulo I; Vianna Bonini Palma P; Zago MA
Haematologica; 2004 Mar; 89(3):273-80. PubMed ID: 15020264
[TBL] [Abstract][Full Text] [Related]
18. Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA).
Sumoza A; de Bisotti R; Sumoza D; Fairbanks V
Am J Hematol; 2002 Nov; 71(3):161-5. PubMed ID: 12410569
[TBL] [Abstract][Full Text] [Related]
19. Clinical follow-up of hydroxyurea-treated adults with sickle cell disease.
Nzouakou R; Bachir D; Lavaud A; Habibi A; Lee K; Lionnet F; Hulin A; Jouault H; Préhu C; Roudot-Thoraval F; Girot R; Galactéros F
Acta Haematol; 2011; 125(3):145-52. PubMed ID: 21196716
[TBL] [Abstract][Full Text] [Related]
20. Effects of hydroxyurea in a population of Brazilian patients with sickle cell anemia.
Vicari P; Barretto de Mello A; Figueiredo MS
Am J Hematol; 2005 Mar; 78(3):243-4. PubMed ID: 15726590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
